

**AMENDMENTS TO THE CLAIMS**

**Listing of Claims:**

This listing of claims is to replace all previous listings.

77. (Previously Amended) A composition comprising:  
a pharmaceutically acceptable carrier;  
a compound chosen from a potassium channel opener, a potassium channel agonist  
and an adenosine receptor agonist; and  
a local anesthetic;  
wherein the compound and the local anesthetic are present in the composition in  
amounts sufficient to arrest the heart; and  
wherein the pharmaceutically acceptable carrier includes potassium at a concentration  
of less than about 10mM.

78. (Previously Amended) The composition of claim 77, wherein the  
potassium channel opener or potassium channel agonist is selected from nicorandil,  
diazoxide, minoxidil, pinicadil, aprikalim, cromokulim, NS-1619 (1,3-dihydro-1-[2-  
hydroxy5(trifluoromethyl)phenyl]5-(trifluoromethyl)2-H-benimidazol-one), amlodipine, Bay  
K 8644(L-type)(1,4-dihydro-26-dimethyl-5-nitro-4[2(trifluoromethyl)phenyl]-3-pyridine  
carboxylic acid (methyl ester)), bepridil HC1 (L-type), calciseptine (L-type), omega-  
conotoxin GVIA (N-type), omega-conotoxin MVIIIC (Q-type), cyproheptadine HC1,  
dantrolene sodium (Ca<sup>2+</sup> release inhibitor), diltiazem HC1 (L-type), filodipine, flunarizine  
HC1 (Ca<sup>2+</sup>/Na<sup>+</sup>), fluspirilene (L-type), HA-1077 2HC1(1-(5 isoquinoliny1 sulphonyl) homo  
piperazine.HC1), isradipine, loperamide HC1, manoalide (Ca<sup>2+</sup> release inhibitor), nicardipine  
HC1 (L-type), nifedipine (L-type), niguldipine HC1 (L-type), nimodipine (L-type),  
nitrendipine (L-type), pimozide (L- and T- type), ruthenium red, ryanodine (SR channels),  
taicatoxin, verapamil HC1 (L-type), methoxy-verapamil HC1 (L-type), YS-035 HC1 (L-  
type)N[2(3,4-dimethoxyphenyl)ethyl]-3,4-dimethoxy N-methyl benzene ethaneamine HC1  
and AV blockers.

79. (Previously Amended) The composition of claim 77, wherein the adenosine receptor agonist is selected from N<sup>6</sup>-cyclopentyladenosine (CPA), N-ethylcarboxamido adenosine (NECA), 2-[p-(2-carboxyethyl)phenethyl-amino-5'-N-ethylcarboxamido adenosine (CGS-21680), 2-chloroadenosine, N<sup>6</sup>-[2-(3,5-dimethoxyphenyl)-2-(2-methoxyphenyl]ethyladenosine, 2-chloro-N<sup>6</sup>-cyclopentyladenosine (CCPA), N-(4-aminobenzyl)-9-[5-(methylcarbonyl)-beta-D-robofuranosyl]-adenine (AB-MECA), ([IS-[1a, 2b, 3b, 4a(S<sup>+</sup>)]]-4-[7-[[2-(3-chloro-2-thienyl)-1-methyl-propyl]amino]-3H-imidazole[4,5-b]pyridyl-3-yl]cyclopentane carboxamide (AMP579, N<sup>6</sup>-(R)-phenylisopropyladenosine (R-PLA), aminophenylethyladenosine [9](APNEA) and cyclohexyladenosine (CHA).

80. (Previously Amended) The composition of claim 77, wherein the local anesthetic is selected from mexiletine, diphenylhydantoin, prilocaine, procaine, mepivacaine and Class 1B antiarrhythmic agents.

81. (Previously Amended) The composition of claim 80, wherein the Class 1B antiarrhythmic agents is lignocaine.

82. (Withdrawn)

83. (Cancelled)

84. (Previously Amended) The composition of claim 77, wherein the pharmaceutically acceptable carrier comprises a buffer which maintains the pH of the composition in the range from about 6 to about 9.

85. (Withdrawn)

86. (Cancelled)

87. (Previously Amended) The composition of claim 84, wherein the buffer

Applicants: Geoffrey P. DOBSON et al.  
Serial No. 09/937,181

is selected from the group consisting of Krebs-Henseleit, St. Thomas No. 2 solution, Tyrodes solution, Femes solution, Hartmanns solution and Ringers-Lactate.

*Cancelled*  
88. (Withdrawn)

89. (Previously Amended) The composition of claim 77, wherein the pharmaceutically acceptable carrier comprises magnesium having a concentration of about 2.5 mM.

*Cancelled*  
90. (Withdrawn)

91. (Previously Amended) The composition of claim 77, further comprising a medicament chosen from dipyridamole and a clot-busting drug.

92. (Previously Presented) The composition of claim 91, wherein the clot-busting drug is streptokinase.

93. (Previously Presented) The composition of claim 78, wherein the AV blocker is adenosine.

94-112. (Cancelled)

113. (New) A method for arresting, preserving, and/or protecting an organ comprising adding or administering an effective amount of a composition according to claim 77.

114. (New) The method of claim 113 wherein the organ is a heart either intact in the body of a subject or isolated.

115. (New) The method of claim 114 wherein the heart is arrested during open-

heart surgery.

116. (New) A method according to claim 113, wherein the potassium channel opener or potassium channel agonist is selected from nicorandil, diazoxide, minoxidil, pinicadil, aprikalim, cromokulim, NS-1619 (1,3-dihydro-1-[2-hydroxy5(trifluoromethyl)phenyl]5-(trifluoromethyl)2-H-benimidazol-one), amlodipine, Bay K 8644(L-type)(1,4-dihydro-26-dimethyl-5-nitro-4[2(trifluoromethyl)phenyl]-3-pyridine carboxylic acid (methyl ester)), bepridil HC1 (L-type), calciseptine (L-type), omega-conotoxin GVIA (N-type), omega-conotoxin MVIIIC (Q-type), cyproheptadine HC1, dantrolene sodium ( $\text{Ca}^{2+}$  release inhibitor), diltiazem HC1 (L-type), filodipine, flunarizine HC1 ( $\text{Ca}^{2+}/\text{Na}^+$ ), fluspirilene (L-type), HA-1077 2HC1(1-(5 isoquinolinyl sulphonyl) homo piperazine.HC1), isradipine, loperamide HC1, manoalide ( $\text{Ca}^{2+}$  release inhibitor), nicardipine HC1 (L-type), nifedipine (L-type), niguldipine HC1 (L-type), nimodipine (L-type), nitrendipine (L-type), pimozide (L- and T- type), ruthenium red, ryanodine (SR channels), taicatoxin, verapamil HC1 (L-type), methoxy-verapamil HC1 (L-type), YS-035 HC1 (L-type)N[2(3,4-dimethoxyphenyl)ethyl]-3,4-dimethoxy N-methyl benzene ethaneamine HC1 and AV blockers.

117. (New) A method according to claim 113, wherein the adenosine receptor agonist is selected from N<sup>6</sup>-cyclopentyladenosine (CPA), N-ethylcarboxamido adenosine (NECA), 2-[p-(2-carboxyethyl)phenethyl-amino-5'-N-ethylcarboxamido adenosine (CGS-21680),2-chloroadenosine, N<sup>6</sup>-[2-(3,5-dimethoxyphenyl)-2-(2-methoxyphenyl]ethyladenosine, 2-chloro-N<sup>6</sup>-cyclopentyladenosine (CCPA), N-(4-aminobenzyl)-9-[5-(methylcarbonyl)-beta-D-robofuranosyl]-adenine (AB-MECA), ([IS-[1a, 2b, 3b, 4a(S<sup>+</sup>)]]-4-[7-[[2-(3-chloro-2-thienyl)-1-methyl-propyl]amino]-3H-imidazole[4,5-b]pyridyl-3-yl]cyclopentane carboxamide (AMP579, N<sup>6</sup>-(R)-phenylisopropyladenosine (R-PLA), aminophenylethyladenosine [9](APNEA) and cyclohexyladenosine (CHA).

118. (New) A method according to claim 113, wherein the local anesthetic is selected from mexiletine, diphenylhydantoin, prilocaine, procaine, mepivacaine and Class 1B antiarrhythmic agents.

119. (New) A method according to claim 113, comprising a buffer selected from the group consisting of Krebs-Henseleit, St. Thomas No. 2 solution, Tyrodes solution, Femes solution, Hartmanns solution and Ringers-Lactate.

120. (New) A method according to claim 113, the composition further comprising a medicament chosen from dipyridamole and a clot-busting drug.

121. (New) A method according to claim 114, comprising arresting the heart with the composition.

122. (New) A method according to claim 121, further comprising preserving and/or protecting the heart with the composition.